Metastatic Bladder Carcinoma: Clinical Trials

4 trials for Metastatic Bladder Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 recruiting. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Recruiting 2

Follow Metastatic Bladder Carcinoma: new trials by email Literature Review of Metastatic Bladder Carcinoma trials Research Report on Metastatic Bladder Carcinoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Biospecimen Collection, Computed Tomography, Enfortumab Vedotin - Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma
Phase 2RecruitingEmory University252023-09-262026-07-29
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2Active not recruitingM.D. Anderson Cancer Center352021-09-232026-09-16
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)602020-11-032026-11-12
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Phase 2RecruitingNational Cancer Institute (NCI)3142019-05-132026-11-12

Narrower conditions

Urinary Bladder Neoplasms (4)  ·  Urachal adenocarcinoma (2)  ·  Ureteral Neoplasms (2)  ·  Urethral Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)  ·  Penile Neoplasms (1)  ·  Prostatic Neoplasms (1)  ·  Urogenital Neoplasms (1)

Broader conditions

Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Male Urogenital Diseases (4)  ·  Neoplasms (4)  ·  Neoplasms by Site (4)  ·  Urinary Bladder Diseases (4)  ·  Urogenital Diseases (4)  ·  Urologic Diseases (4)  ·  Urologic Neoplasms (4)  ·  Urogenital Neoplasms (3)  ·  Neoplasms by Histologic Type (2)  ·  Ureteral Diseases (2)  ·  Urethral Diseases (2)  ·  Adenocarcinoma (1)  ·  Bronchial Neoplasms (1)

Interventions

Magnetic Resonance Spectroscopy (3)  ·  Specimen Handling (3)  ·  CTLA-4 Antigen (2)  ·  Ipilimumab (2)  ·  Nivolumab (2)  ·  Biopsy (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  cabozantinib (1)  ·  enfortumab vedotin (1)  ·  olaparib (1)  ·  pembrolizumab (1)  ·  tocilizumab (1)

Sponsors

National Cancer Institute (NCI) (2)  ·  Emory University (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (4)  ·  Puerto Rico (1)

Top investigators

Andrea B Apolo (2)  ·  Jacqueline Brown, MD (1)  ·  Rodabe Amaria, MD (1)

Results publications

PMID 35031545, PMID 35537412, PMID 37328287

NIH funding

P30CA138292 (1), U10CA180821 (1), ZIABC011078 (1)